Corvus Pharmaceuticals, Inc.
NasdaqGM:CRVS Lagerbericht
Marktkapitalisierung: US$591.1m
Corvus Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 2/6 Corvus Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 7.1% bzw. 76.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 14.9% pro Jahr wachsen soll.
Wichtige Informationen
7.1%
Wachstumsrate der Gewinne
Biotechs Gewinnwachstum 27.3% Wachstumsrate der Einnahmen 76.9% Zukünftige Eigenkapitalrendite n/a Analystenabdeckung Low
Zuletzt aktualisiert 22 Oct 2024
Jüngste Aktualisierungen zum künftigen Wachstum
Price target increased by 9.1% to US$7.50 Mar 30
Price target decreased to US$2.50 Nov 16
Price target increased to US$6.38 Apr 27
Price target increased to US$6.30 Dec 05
Price target increased to US$7.38 May 27
Price target decreased to US$6.50 Apr 12
Alle Updates anzeigen
Corvus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy Sep 02 Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Aug 07
Corvus Pharmaceuticals, Inc Grants FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Aug 02
Corvus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 01 Corvus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $30.567011 million. May 08
Corvus Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $30.567011 million. May 03
Corvus Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024 Apr 28
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Apr 10
Price target increased by 9.1% to US$7.50 Mar 30
Corvus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024 Mar 14
New minor risk - Market cap size Mar 11
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely? Mar 06
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases Feb 13
New major risk - Revenue and earnings growth Feb 10
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer Feb 07
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors Jan 24
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial Dec 11
New major risk - Financial position Nov 10
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases Nov 02
Corvus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation Oct 23
Corvus Pharmaceuticals, Inc. Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Sep 08
New major risk - Revenue and earnings growth Aug 10
New minor risk - Market cap size Aug 08
Corvus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Corvus Pharmaceuticals, Inc. Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference Jun 30
New minor risk - Market cap size Jun 21
Corvus Pharmaceuticals, Inc. Presents New Cpi-818 Interim Data At the International Conference on Malignant Lymphoma Jun 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth? May 16
Corvus Pharmaceuticals, Inc. Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition Dec 13
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation Dec 05
Price target decreased to US$2.50 Nov 16
Insufficient new directors Nov 16
Corvus Pharmaceuticals, Inc. to Present Updated CPI-818 (ITK Inhibitor) Data At the American Society of Hematology Annual Meeting & Exposition Nov 04
Corvus Pharmaceuticals Receives Written Notice from the Staff of the Listing Qualifications Department of Nasdaq Oct 31
Corvus Pharmaceuticals, Inc. Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer Oct 26
Corvus Pharmaceuticals, Inc. Announces Partner Angel Pharmaceuticals Receives IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China Sep 27
Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China Sep 26
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate Aug 14
Corvus Pharmaceuticals, Inc. Provides Business and Clinical Update Aug 10
Corvus Pharmaceuticals, Inc. Appoints Dr. James Rosenbaum as Senior Vice President of Research Jul 22
Price target increased to US$6.38 Apr 27
Insufficient new directors Apr 27
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth Apr 05
Chief Financial Officer recently bought US$77k worth of stock Mar 18
Corvus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
Insufficient new directors Feb 03
Corvus Pharmaceuticals, Inc. Announces New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as A Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely Dec 15
Checking In On Corvus Pharmaceuticals Dec 10
Price target increased to US$6.30 Dec 05
Corvus Pharmaceuticals Provides Updates on Mupadolimab Sep 24
Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming Sep 22
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth Aug 26
Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations Jul 16
Independent Director Steve Krognes has left the company Jun 19
Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target May 27
Price target increased to US$7.38 May 27
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans? May 08
Co-Founder recently bought US$100k worth of stock May 07
Price target decreased to US$6.50 Apr 12
Co-Founder recently bought US$350k worth of stock Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares Feb 19
New 90-day high: US$4.28 Feb 09
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation Feb 07
Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19 Feb 05
New 90-day low: US$3.77 Dec 29
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like Dec 16 Corvus Pharmaceuticals, Inc. Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals EPS misses by $0.06 Oct 29
Corvus Pharmaceuticals, Inc. Announces Updated Data from Its Ongoing Phase 1 Study Investigating the Potential for CPI-006 Oct 06
Corvus Pharmaceuticals, Inc. Announces New Data from its Clinical Collaboration with Genentech Sep 17
Corvus Pharmaceuticals, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 24
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell Microcap Value Index Jul 03
Gewinn- und Umsatzwachstumsprognosen NasdaqGM:CRVS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions) Datum Umsatz Gewinne Freier Cashflow Bargeld aus operativen Tätigkeiten Durchschn. Anz. Analysten 12/31/2026 5 -47 -40 N/A 5 12/31/2025 1 -37 -29 N/A 5 12/31/2024 N/A -25 -22 N/A 5 6/30/2024 N/A -23 -21 -21 N/A 3/31/2024 N/A -25 -21 -21 N/A 12/31/2023 N/A -27 -24 -24 N/A 9/30/2023 N/A -30 -26 -26 N/A 6/30/2023 N/A -39 -28 -28 N/A 3/31/2023 N/A -41 -29 -29 N/A 12/31/2022 N/A -41 -27 -27 N/A 9/30/2022 N/A -41 -27 -26 N/A 6/30/2022 N/A -37 -28 -28 N/A 3/31/2022 N/A -40 -34 -34 N/A 12/31/2021 N/A -43 -37 -37 N/A 9/30/2021 N/A -7 -38 -38 N/A 6/30/2021 N/A -6 -37 -37 N/A 3/31/2021 N/A -5 -34 -34 N/A 12/31/2020 N/A -6 -35 -35 N/A 9/30/2020 N/A -44 -35 -35 N/A 6/30/2020 N/A -46 -38 -38 N/A 3/31/2020 N/A -48 -38 -38 N/A 12/31/2019 N/A -47 -37 -37 N/A 9/30/2019 N/A -46 -37 -37 N/A 6/30/2019 N/A -46 -38 -37 N/A 3/31/2019 N/A -44 -39 -39 N/A 12/31/2018 N/A -47 -41 -41 N/A 9/30/2018 N/A -48 -44 -44 N/A 6/30/2018 N/A -51 -44 -44 N/A 3/31/2018 N/A -54 N/A -45 N/A 12/31/2017 N/A -56 N/A -46 N/A 9/30/2017 N/A -55 N/A -45 N/A 6/30/2017 N/A -52 N/A -41 N/A 3/31/2017 N/A -46 N/A -35 N/A 12/31/2016 N/A -36 N/A -28 N/A 9/30/2016 N/A -31 N/A -22 N/A 6/30/2016 N/A -24 N/A -19 N/A 3/31/2016 N/A -36 N/A -15 N/A 12/31/2015 N/A -31 N/A -11 N/A 9/30/2015 N/A -25 N/A -7 N/A
Mehr anzeigen
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CRVS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: CRVS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: CRVS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: CRVSDie Einnahmen des Unternehmens (76.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: CRVSDie Einnahmen des Unternehmens (76.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CRVS in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
